Int J Med Sci 2021; 18(7):1554-1565. doi:10.7150/ijms.52846

Research Paper

Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis

Di Hu, MD1*, Junhong Jiang, MD2*, Zhong Lin, MD, PhD2, Cong Zhang, MD2, Nived Moonasar, MBBS, MS3, Shaohong Qian, Prof, MD1 Corresponding address

1. Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
2. The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, China.
3. Caribbean Eye Institute, Valsayn, Trinidad and Tobago.
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Hu D, Jiang J, Lin Z, Zhang C, Moonasar N, Qian S. Identification of key genes and pathways in scleral extracellular matrix remodeling in glaucoma: Potential therapeutic agents discovered using bioinformatics analysis. Int J Med Sci 2021; 18(7):1554-1565. doi:10.7150/ijms.52846. Available from

File import instruction


Background: Glaucoma is a leading cause of irreversible blindness. Remodeling of the scleral extracellular matrix (ECM) plays an important role in the development of glaucoma. The aim of this study was to identify the key genes and pathways for the ECM remodeling of sclera in glaucoma by bioinformatics analysis and to explore potential therapeutic agents for glaucoma management.

Methods: Genes associated with glaucoma, sclera and ECM remodeling were detected using the text mining tool pubmed2ensembl, and assigned Gene Ontology (GO) biological process terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using the GeneCodis program. A protein-protein interaction (PPI) network was constructed by STRING and visualized in Cytoscape, module analysis was performed using the Molecular Complex Detection (MCODE) plugin, and GO and KEGG analyses of the gene modules were performed using the Database of Annotation, Visualization and Integrated Discovery (DAVID) platform. The genes that clustered in the significant module were selected as core genes, and functions and pathways of the core genes were visualized using ClueGO and CluePedia. Lastly, the drug-gene interaction database was used to explore drug-gene interactions of the core genes to find drug candidates for glaucoma.

Results: We identified 125 genes common to “Glaucoma”, “Sclera”, and “ECM remodeling” by text mining. Gene functional enrichment analysis yielded 30 enriched GO terms and 20 associated KEGG pathways. A PPI network that included 60 nodes with 249 edges was constructed, and three gene modules were obtained using the MCODE. We selected 13 genes that clustered in module 1 as core candidate genes that were associated mainly with ECM degradation and cell proliferation and division. The HIF-1 signaling pathway, FOXO signaling pathway, PI3K-Akt signaling pathway and TGFB signaling pathway were found to be enriched. We found that 11 of the 13 selected genes could be targeted by 26 existing drugs.

Conclusions: The results showed that VEGFA, TGFB1, TGFB2, TGFB3, IGF2, IGF1, EGF, FN1, KNG1, TIMP1, SERPINE1, THBS1, and VWF were potential key genes involved to scleral ECM remodeling. Furthermore, 26 drugs were identified as potential therapeutic agents for glaucoma treatment and management.

Keywords: glaucoma, sclera, extracellular matrix, text mining, drug discovery


Glaucoma is a progressive optic neuropathy characterized by progressive degeneration of retinal ganglion cells and optic nerve head (ONH) axons [1]. The global prevalence of glaucoma is 3.54% in the population aged 40-80 years, and glaucoma was estimated to have affected 76 million people worldwide in 2020 [2]. Glaucoma is a leading cause of irreversible blindness, and it was estimated that 9.4 million people are bilaterally blind as a result of glaucoma worldwide [3]. Glaucoma-related visual impairment can significantly reduce the quality of life, causing heavy economic burden to individuals and by extension to the society at large. With an aging global population, the number of patients with glaucoma is projected to grow to 111.8 million by 2040 [2], and the overall burden of glaucoma treatment will continue to increase.

Currently, lowering of intraocular pressure (IOP) (by medication, laser/or filtering surgery) is the only available option to delay the development and progression of glaucoma [4]. However, treatments that reduce IOP prevent vision loss in only 50%-70% of patients with glaucoma, and thus nearly a half of the patients will experience glaucomatous progression despite the IOP within the normal range [5, 6]. Clearly, a more effective therapy for the treatment and prevention of glaucoma is urgently needed.

Retinal ganglion cell axons converge at the ONH, pass through the laminar cribrosa, enter the scleral canal and exit the eye [7]. The biomechanical transmission of stress from IOP produces strain in the ONH and leads to retinal ganglion cell axonal injury and vascular perfusion deficiency, eventually leading to glaucomatous optic neuropathy [8, 9]. ONH is the principal site of glaucomatous damage [10], and the IOP-related biomechanical response of ONH is determined by the mechanical properties of sclera, especially the adjacent peripapillary sclera [11].

Stiffening of the sclera leading to scleral rigidity is one of the primary structural changes in glaucoma [12, 13]. Sclera consists of fibroblasts and extracellular matrix (ECM), which is made up of collagen, elastin, and proteoglycans [8, 14]. Scleral fibroblasts are mechanosensitive, and elevated IOP can induce them to differentiate into myofibroblasts, resulting in ECM remodeling, which involves scleral fibroblast proliferation, followed by fibrosis of the sclera with alterations in the biomechanical properties [14, 15]. Finite element modeling and ex vivo studies have shown that the biomechanical strain within the laminar cribrosa depends on the stiffness of the sclera, and that increased peripapillary sclera stiffness can reduce the laminar cribrosa strain [16, 17]. In an in vivo experiment, mice with microfibril deficiency were shown to have increased susceptibility to glaucomatous damage [18], whereas increased mechanical stiffness of the sclera was found to result in increased glaucomatous damage in a mouse model [19]. Therefore, scleral ECM remodeling might be a suitable drug target for preventing the biomechanical damage associated with glaucoma.

The discovery of new drug therapies using conventional approaches can be time-consuming and costly, whereas repurposing an existing drug to treat a condition beyond its original intent may be a more effective and less expensive alternative [20]. Text mining of biomedical literature is as an effective method for hypothesis generation, because it can reveal novel associations between genes and pathologies [21]. By combining text mining with biological knowledge and other analytical tools, new information about the potential to repurpose existing drugs can be obtained [22]. The aim of this study was to investigate therapeutic targets and new drug therapies for glaucoma by mining the available published literature combined with biological databases and other analytical tools.


Text mining

Text mining was performed using pubmed2ensembl (, a publicly available resource that links over 2,000,000 articles in PubMed to nearly 150,000 genes from 50 species in Ensembl [23]. We used the search terms “Glaucoma”, “Sclera” and “ECM remodeling” from 100,000 relevant document IDs to produce a list of genes. “Homo sapiens (GRCh37)” was selected as the species dataset and “filter on MEDLINE: PubMed ID” was set to constrain the query result. The unduplicated genes were extracted and the intersection of gene hits from the three gene sets was retrieved as the text mining genes (TMGs).

Biological process and pathway enrichment analysis of TMGs

We used GeneCodis ( to perform an enrichment analysis of the TMGs related to scleral ECM remodeling in glaucoma. GeneCodis is a web‑based server for functional analysis of gene lists that integrates different sources of information [24]. The TMGs were used as the input set and analyzed using the gene ontology (GO) biological process categories, and genes with significantly enriched biological processes were selected and used for further analysis of enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations. P =1.00E-07 was set as the cutoff. Genes involved in the significantly enriched KEGG pathways were used for further analysis.

Integration of protein-protein interaction (PPI) network and module analysis

The Search Tool for the Retrieval of Interacting Genes (STRING, is an online database resource that covers approximately 24.6 million proteins and more than 3.1 billion interactions originating from 5090 organisms [25]. We used STRING (version 11.0) to construct PPI networks of the selected genes. The highest confidence score (0.900) was set as the minimum required interaction score. Molecular interaction networks were visualized using Cytoscape [26], and significant gene modules (clusters) from the PPI network were detected using the Molecular Complex Detection (MCODE) built in Cytoscape, with the following criteria: degree cutoff =2, node score cutoff=0.2, k-core=2, max depth=100 [27].

 Figure 1 

Summary of the study design. Text mining was conducted using pubmed2ensembl to identify genes associated with glaucoma, sclera, and extracellular matrix (ECM) remodeling. Gene set enrichment was performed using GeneCodis to detect genes enriched in gene ontology (GO) biological process terms and KEGG pathways. STRING and MCODE were used to construct a protein-protein interaction network and identify modules. The GO biological process terms and KEGG pathways were analyzed using DAVID and ClueGO. The drug list was obtained based on the gene-drug interaction analysis conducted using the drug-gene interaction database (DGIdb). KEGG: Kyoto Encyclopedia of Genes and Genomes.

Int J Med Sci Image (Click on the image to enlarge.)

Gene ontology and KEGG pathway enrichment analysis of module genes

The GO functional and KEGG pathway enrichment analyses of significant module genes were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID) (, an online tool for gene functional analysis [28]. P < 0.05 was set as the cutoff. The GO ( database contains terms for the functional classification for genomic data under three main categories: biological processes, cellular component, and molecular function [29]. KEGG ( is a knowledge base for systematic analysis, annotation, and visualization of gene functions [30]. The GO functional and KEGG pathway enrichment analyses of the core genes was performed and visualized using the Cytoscape plugins ClueGO (version 2.5.7), and CluePedia (version 1.5.7) [31]. P < 0.01 was considered statistically significant.

Drug-gene interactions

The drug-gene interaction database (DGIdb, www. is a web resource that consolidates disparate data sources that describe drug-gene interactions and gene druggability [32]. We used DGIdb (version 3.0) to explore drug-gene interactions in the significant module genes that were identidied as the potential targets for existing drugs or compounds.


Identification of text mining genes (TMGs)

Using the text mining strategy described in the methods section (Figure 1), we obtain 911 unique genes related to glaucoma, 839 related to ECM remodeling, 311 related to sclera; among them, 125 genes were related to all three, and thus we considered them to be involved in scleral ECM remodeling in glaucoma (Figure 2A, Table S1).

Enrichment analysis of TMGs

The GO biological process terms and KEGG pathway enrichment analyses using GeneCodis (with P=1.00E-07 as the cutoff) to identified the most enriched terms closely related to the pathology of scleral ECM remodeling in glaucoma. Thirty significantly enriched GO biological process annotations of 97 unique genes were identified. Among them, the five most enriched terms were “extracellular matrix organization” (P=3.47306E-27), “platelet degranulation” (P=2.44362E-19), “cytokine-mediated signaling pathway” (P=3.99419E-18), “response to drug” (P=3.82E-14), and “positive regulation of cell population proliferation” (P=1.45E-13), for 31, 20, 25, 22, and 27 TMGs, respectively (Table 1). Other highly enriched biological process terms included “response to hypoxia”, “wound healing”, “regulation of cell population proliferation”, “response to mechanical stimulus”, “extracellular matrix disassembly”, and “aging” (Table S2).

The KEGG pathway enrichment analysis identified 20 significant pathways that involved 64 TMGs. The five most significantly enriched pathways were “AGE-RAGE signaling pathway in diabetic complications” (P=1.04E-22), “Proteoglycans in cancer” (P=3.04E-19), “Pathways in cancer” (P=1.88327E-16), “HIF-1 signaling pathway” (P=1.17E-12), and “Relaxin signaling pathway” (P= 1.34E-12), involving 23, 26, 34, 16, and 17 TMGs, respectively (Table 2). Other highly enriched pathways included “PI3K-Akt signaling pathway”, “MAPK signaling pathway”, “Rheumatoid arthritis”, “FOXO signaling pathway”, “Focal adhesion” and “Endocrine resistance” (Table S3).

PPI network construction, modular analysis, and identification of core candidate genes

A PPI network was constructed for the 64 target genes using STRING with confidence score >0.900. The network had a total of 60 nodes with 249 edges (Figure 2B). Among the 60 nodes, 22 hub node genes were identified with filtering node degree ≥10 (Table 3). Modular analysis was performed using the MCODE built in Cytoscape, and three modules were obtained (Figure 2C-E).

The GO enrichment analysis showed that the three modules were related primarily to ECM degrading, cell proliferation and division which play crucial role in scleral ECM remodeling (Figure 3A,C,D). The pathway enrichment analysis showed that the genes in module 1 were associated with the HIF-1 signaling pathway, FOXO signaling pathway, PI3K-Akt signaling pathway and TGFB signaling pathway (Figure 3B). No specific KEGG pathways were associated with the genes in module 2, and the genes in module 3 were significantly associated with metallopeptidase or metalloendopeptidase activity, NOD-like receptor or RIG-I-like receptor signaling pathway, and NF-kappa B signaling pathway (Table 4).

Module 1 contained 13 genes with 88 edges, all of which were hub genes indicating that module 1 has a vital role in the PPI network. We selected the 13 hub genes, TGFB1, TGFB2, TGFB3, VEGFA, IGF2, IGF1, EGF, FN1, KNG1, TIMP1, SERPINE1, THBS1 and VWF, as core candidate genes of the PPI network. The enrichment analysis indicated that these genes were significantly enriched in platelet alpha granule lumen, HIF-1 signaling pathway, and AGE-RAGE signaling pathway in diabetic complication (P <0.01, Figure 4).

 Figure 2 

Identification and enrichment analysis of the text mining genes (TMGs). (A) Venn diagram of the TMGs related to glaucoma, extracellular matrix (EMC) remodeling, and sclera. The 125 genes that were common were considered to be related to scleral EMC remodeling. (B) The protein-protein interaction (PPI) network of the 64 target TMGs was visualized using Cytoscape. (C-E) The three modules were obtained from PPI network using MCODE. (C) Module 1, the most significant module with 13 nodes; (D) Module 2; (E) Module 3.

Int J Med Sci Image (Click on the image to enlarge.)
 Table 1 

Top 15 enriched gene ontology (GO) biological process terms assigned to the text mining genes

ProcessGenes in
query set
Total genes in genomeCorrected hypergeometric P valueGenes
Extracellular matrix organization312573.47E-27CDH1, CD44, VWF, VTN, VCAM1, TNF, THBS1, TGFBI, SPARC, BGN, SERPINE1, NID1, MMP14, MMP9, MMP3, MMP2, MMP1, MFAP2, LUM, ITGAL, ICAM1, TNC, FN1, FGF2, FBN1, ELN, COL18A1, DCN, VCAN, COL1A2, COL1A1.
Platelet degranulation201252.44E-19CLU, MMRN1, VWF, VEGFA, TIMP1, THBS1, TGFB3, TGFB2, TGFB1, TF, SPARC, SOD1, SERPINE1, KNG1, IGF2, IGF1, APOA1, FN1, ALB, EGF.
Cytokine-mediated signaling pathway252903.99E-18CDKN1A, CD4, VIM, VEGFA, VCAM1, TWIST1, TNF, TIMP1, TGFB1, BCL2, NOS2, MMP9, MMP3, MMP2, MMP1, KIT, IL8, IL2, ICAM1, FOS, FN1, FGF2, AKT1, F3, COL1A2.
Response to drug223053.82E-14CDKN1B, CDKN1A, CDH1, CAT, TIMP2, THBS1, TGFBR2, TGFB2, SST, SOD1, BCL2, REN, PTCH1, APOA1, ICAM1, APEX1, FOS, ENG, EDN1, COL18A1, CTNNB1, COL1A1.
Positive regulation of cell population Proliferation275571.45E-13CDKN1B, CNOT8, VEGFA, TIMP1, THBS1, TGFBR2, TGFB3, TGFB2, TGFB1, SHH, RPS4X, BCL2, KIT, IL2, IGF2, IGF1, TNC, FN1, FLT1, FGF2, AKT1, AGT, EGFR, EGF, EDN1, COL18A1, CTNNB1.
Response to hypoxia171747.16E-13CDKN1B, CAT, VEGFA, THBS1, TGFBR2, TGFB3, TGFB2, BMP2, PLAU, PLAT, NOS2, NOS1, MMP14, MMP2, ICAM1, ENG, EDN1.
Wound healing141031.99E-12TIMP1, TGFBR2, TGFB3, TGFB2, SPARC, IGF1, TNC, GSN, FN1, FGF2, ENG, EGFR, DCN, COL1A1.
Regulation of cell population Proliferation182222.05E-12CLU, CDKN1B, TNF, TGFBR2, TGFB3, TGFB2, TGFB1, SPARC, SHH, PTCH1, PLAU, NOS2, KIT, TNC, ENG, AGT, EGFR, CTNNB1.
Negative regulation of gene expression203104.16E-12CDKN1A, CD34, VEGFA, TNF, TGFB2, TGFB1, BMP2, SHH, SERPINF1, NOS2, MAX, IL8, IGF1, FGF2, AKT1, ENG, AGT, EDN1, ACE, CTNNB1.
Positive regulation of gene expression244984.56E-12CLU, CD34, VIM, VEGFA, TWIST1, TNF, TGFB1, BMP2, SHH, MAPK8, MAPK3, NOS3, KIT, IL8, IGF1, TNC, GSN, GJA1, FN1, AKT1, F3, ENG, EGF, CTNNB1.
Positive regulation of cell migration182551.66E-11VEGFA, THBS1, TGFB1, BMP2, SOD2, PLAU, MMP14, MMP9, KIT, IGF1, HSPA5, FLT1, F3, EGFR, EGF, EDN1, COL18A1, COL1A1.
Cellular protein metabolic process162263.55E-10CALCA, TIMP1, TGFBI, TF, MMP2, MMP1, KNG1, IGF2, IGF1, APOA1, TNC, GSN, FN1, ALB, FBN1, VCAN.
Regulation of blood pressure10631.50E-09CD34, CALCA, SOD2, SOD1, REN, NOS3, AGT, EDN1, ACE, COL1A2.
Positive regulation of MAP kinase activity10631.50E-09VEGFA, TNF, TGFB1, KIT, GH1, FLT1, FGF2, EGFR, EGF, EDN1.
 Table 2 

Top 10 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways assigned to the text mining genes

ProcessGenes in query setTotal genes in genomeCorrected hypergeometric P valueGenes
AGE-RAGE signaling pathway in diabetic complications231001.04E-22CDKN1B, VEGFA, VCAM1, TNF, TGFBR2, TGFB3, TGFB2, TGFB1, BCL2, MAPK8, MAPK3, SERPINE1, NOS3, MMP2, IL8, ICAM1, FN1, AKT1, F3, AGT, EDN1, COL1A2, COL1A1.
Proteoglycans in cancer262053.04E-19CDKN1A, CD44, VTN, VEGFA, TWIST1, TNF, THBS1, TGFB2, TGFB1, SHH, PTCH1, MAPK3, PLAU, MMP9, MMP2, LUM, IGF2, IGF1, FN1, FGF2, AKT1, EGFR, DCN, CTNNB1, COL1A2, COL1A1.
Pathways in cancer345311.88E-16CDKN1B, CDKN1A, CDH1, VEGFA, TGFBR2, TGFB3, TGFB2, TGFB1, BMP2, SHH, BCL2, PTCH1, MAPK8, MAPK3, NOS2, MMP9, MMP2, MMP1, MAX, KNG1, KIT, IL8, IL2, IGF2, IGF1, FOS, FN1, FGF2, AKT1, AGT, EGFR, EGF, EDN1, CTNNB1.
HIF-1 signaling pathway161091.17E-12CDKN1B, CDKN1A, VEGFA, TIMP1, TF, BCL2, MAPK3, SERPINE1, NOS3, NOS2, IGF1, FLT1, AKT1, EGFR, EGF, EDN1.
Relaxin signaling pathway171291.34E-12VEGFA, TGFBR2, TGFB1, MAPK8, MAPK3, NOS3, NOS2, NOS1, MMP9, MMP2, MMP1, FOS, AKT1, EGFR, EDN1, COL1A2, COL1A1.
Chagas disease (American trypanosomiasis)151026.57E-12TNF, TGFBR2, TGFB3, TGFB2, TGFB1, MAPK8, MAPK3, SERPINE1, NOS2, KNG1, IL8, IL2, FOS, AKT1, ACE.
Bladder cancer11411.05E-11CDKN1A, CDH1, VEGFA, THBS1, MAPK3, MMP9, MMP2, MMP1, IL8, EGFR, EGF.
PI3K-Akt signaling pathway233545.42E-11CDKN1B, CDKN1A, VWF, VTN, VEGFA, THBS1, BCL2, MAPK3, NOS3, KIT, IL2, IGF2, IGF1, TNC, GH1, FN1, FLT1, FGF2, AKT1, EGFR, EGF, COL1A2, COL1A1.
Colorectal cancer13861.41E-10CDKN1A, TGFBR2, TGFB3, TGFB2, TGFB1, BCL2, MAPK8, MAPK3, FOS, AKT1, EGFR, EGF, CTNNB1.
Prostate cancer13976.18E-10CDKN1B, CDKN1A, BCL2, MAPK3, PLAU, PLAT, MMP9, MMP3, IGF1, AKT1, EGFR, EGF, CTNNB1.
 Figure 3 

Gene ontology (GO) and KEGG pathway analysis of the genes in the three modules. (A) Top 20 significantly enriched GO terms in module 1. (B) Significantly enriched KEGG pathways in module 1. (C) Significantly enriched GO terms in module 2. (D) Significantly enriched GO terms in module 3. The functional and pathway enrichment analyses were performed using DAVID. KEGG: Kyoto Encyclopedia of Genes and Genomes.

Int J Med Sci Image (Click on the image to enlarge.)
 Table 3 

Hub node genes in the protein-protein interaction network identified with filtering node degree ≥10

NumberGenesDegreeMCODE ClusterMCODE Node Status
1VEGFA24Module 1Seed
2IGF121Module 1Clustered
3EGF20Module 1Clustered
4FN120Module 1Clustered
5TGFB119Module 1Clustered
6KNG119Module 1Clustered
7TIMP118Module 1Clustered
8TGFB317Module 1Clustered
10TGFB216Module 1Clustered
11IGF216Module 1Clustered
12SERPINE115Module 1Clustered
13THBS115Module 1Clustered
17MMP213Module 2Clustered
18VWF13Module 1Clustered
19MMP912Module 3Clustered
20DCN11Module 2Seed

Drug-gene interaction analysis of core genes

We used the 13 core genes as potential targets in a drug-gene interaction analysis, and obtained an initial list of 26 drugs (Table 5). Eleven of the 13 potential gene targets (the exceptions were IGF2 and TIMP1) were predicted to be involved in drug-gene interactions. The primary connection among drugs, genes and pathways are shown in Figure 5.


Glaucoma is the leading cause of irreversible blindness globally. Reduction of IOP is the only proven method to treat glaucoma [7]. However, many patients who are treated with IOP-lowering therapies have poor prognosis, and nearly a half of patients with glaucoma experience glaucomatous progression despite IOP reduction [33]. Therefore, more therapeutic targets and prognostic biomarkers need to be identified. Stiffening of the sclera, particularly in peripapillary sclera, is one of the primary structural changes in glaucoma. It has been shown that elevated IOP can induce scleral fibroblasts to differentiate into myofibroblasts, resulting in ECM remodeling, followed by stiffening of the sclera [14, 15]. The ONH is the primary site of damage in glaucoma, and stiffening of the peripapillary sclera significantly impacts the biomechanics of the ONH that eventually influence the susceptibility to glaucomatous damage [16-19]. Therefore, ECM remodeling might be an attractive drug target for the prevention and treatment of glaucoma.

In the present study, we identified 125 genes that might be involved in scleral ECM remodeling associated with glaucoma using text mining strategy (Figure 1). The enriched GO biological process terms assigned to these genes were associated mainly with scleral ECM remodeling, including “positive regulation of cell population Proliferation”[34], “response to hypoxia” [35], “aging” [36], “wound healing” [37], “response to mechanical stimulus” [38] and “positive regulation of MAP kinase activity” [39] (Table 1). The PPI network and enrichment analysis identified 13 core genes, TGFB1, TGFB2, TGFB3, VEGFA, IGF2, IGF1, EGF, FN1, KNG1, TIMP1, SERPINE1, THBS1 and VWF, that were involved in the HIF-1 signaling pathway, TGFB signaling pathway, FOXO signaling pathway, and PI3K-Akt signaling pathway.

 Table 4 

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the genes in module 3

TermDescriptionCountP value
hsa05161Hepatitis B34.41E-04
hsa05219Bladder cancer20.011886
hsa04621NOD-like receptor signaling pathway20.016216
hsa04622RIG-I-like receptor signaling pathway20.02025
hsa04064NF-kappa B signaling pathway20.025136
hsa05323Rheumatoid arthritis20.025423
hsa05142Chagas disease20.030011
hsa04620Toll-like receptor signaling pathway20.030583
hsa04668TNF signaling pathway20.030869
hsa05160Hepatitis C20.038297
hsa04932Non-alcoholic fatty liver disease (NAFLD)20.043423
hsa05202Transcriptional misregulation in cancer20.047968
hsa05164Influenza A20.049953
 Figure 4 

Function analysis of the 13 core genes in module 1. (A) Enriched gene ontology (GO) terms and KEGG pathways. (B) Functions and pathways of the core genes were visualized using ClueGO. (C) Distribution of the functions and pathways among the core genes. Each function or pathway is color coded. Corrected P <0.01 was considered statistically significant. KEGG: Kyoto Encyclopedia of Genes and Genomes.

Int J Med Sci Image (Click on the image to enlarge.)
 Figure 5 

Sankey diagram showing the primary connections among drugs, genes, and pathways.

Int J Med Sci Image (Click on the image to enlarge.)
 Table 5 

Details of the 26 drugs that potentially target 11 of the 13 core genes

NumberDrugGenesInteractionScoreDrug ClassApproved?Reference
(PubMed ID)
1Ranibizumab**VEGFAinhibitor14antineoplastic agents, ocular vascular disorder agentsYes*18046235
2BevacizumabVEGFAinhibitor10antineoplastic agent, immunomodulating agentsYes*15705858
3Aflibercept**VEGFAinhibitor7antineoplastic agent, ocular vascular disorder agentsYes*22813448
4CarvedilolVEGFAother5vasodilator agents, neurotransmitter agentsYes*15071347
5Dalteparin sodiumVEGFAinhibitor4hematologic agents, fibrinolytic agentsYes21091776
7VandetanibVEGFAinhibitor1antineoplastic and immunomodulating agentYes*None found
8DusigitumabIGF1inhibitor1not availableNoNone found
9SucralfateEGFinducer4antiulcer agent, antimuscarinicsYes*8578218
10Ocriplasmin**FN1cleavage3not availableYes23193358
11AS-1409FN1binder2antineoplastic agentNoNone found
12L19TNFaFN1N/A1fibronectin binding agentNoNone found
13UrokinaseSERPINE1N/A7thrombolytic agents, fibrinolytic agentsYes*12709915
14TroglitazoneSERPINE1antagonist6hypoglycemic agentsNo10871202
15Drotrecogin alfaSERPINE1N/A5antithrombotic agents, fibrinolytic agents,Yes*12004248
16HydrochlorothiazideKNG1inhibitor1antihypertensive agents, hypotensive agentsYes*None found
17TretinoinTHBS1N/A3antineoplastic agents, dermatologic agents, immunosuppressive agentsYes*9447832
18CorticotropinTHBS1N/A2immunosuppressive agentsYes*8698834
19CamptothecinTHBS1N/A2antineoplastic agentsYes*16962673
20CaplacizumabVWFinhibitor3antithromboticNoNone found
21StreptozotocinVWFinhibitor3antibiotics, antineoplastic agents, immunosuppressive agentsYes*16422885
22ThalidomideVWFN/A2antineoplastic agentsYes*12871448
23HyaluronidaseTGFB1inhibitor5not availableYes*9435505
24Vitamin ETGFB1N/A3antioxidantsYes*1505665
25LerdelimumabTGFB2inhibitor2monoclonal antibodyNoNone found
26FresolimumabTGFB1, TGFB2, TGFB3inhibitor2antineoplastic agentsNoNone found

**Drugs that have been used to treat ophthalmic disease.

*Drugs that have been approved by the US Food and Drug Administration.

Transforming growth factor β (TGFB) belongs to a family of fibrogenic cytokine that includes TGFB1, TGFB2 and TGFB3 [40]. Inhibition of TGFB reduces α-SMA expression, myofibroblast differentiation, and proliferation of scleral fibroblasts in experimental glaucoma [41]. Vascular endothelial growth factor A (VEGFA) is a central regulator of angiogenesis and vascular permeability, and is involved in angiogenesis, inflammatory cell migration, and fibroblast activity [42].VEGF-A can be induced by TGFB1 through the TGFB1-VEGF-A pathway, resulting in fibrosis in patients who undergo peritoneal dialysis [43]. Inhibition of VEGF was shown to improve the surgical outcome of glaucoma surgery by reducing angiogenesis and fibrosis in experimental models [44]. Insulin-like growth factor 1 (IGF1) is a pro‐fibrotic growth factor that stimulates fibroblast proliferation and collagen synthesis in idiopathic pulmonary fibrosis [45]. IGF2 is involved in inflammation and fibrosis, and the IGF2 plasma levels were closely associated with the stages of liver fibrosis [46]. Epidermal growth factor (EGF) is an essential growth factor in stimulating cell proliferation, which plays a role in the progression of fibrosis in the liver [47]. Fibronectin 1(FN1) is involved in cell adhesion and migration, which is required for the accumulation of ECM components [48], and the interaction of FN1 with the cell surface is essential for TGFB-mediated activation of fibrogenic cells [49]. SERPINE1, also called plasminogen activator inhibitor type 1 (PAI‐1), is a fibrinolysis inhibitor that contributes to fibrogenesis by decreasing the degradation of fibrin and other ECM proteins through the uPA/tPA/plasmin/MMP proteolytic system [50]. Kininogen-1 (KNG1) is a multifunctional protein that plays an important role in fibrinolysis and inflammation [51]. Tissue inhibitor of metalloproteinase 1 (TIMP1) is a glycoprotein in the TIMP family that plays a role in matrix remodeling by activating macrophages and inhibiting matrix metalloproteinases (MMPs) [52]. Thrombospondin-1 (THBS1) belongs to the thrombospondin family of glycoproteins that are important components of the ECM [53]. Gao et al. [54] demonstrated that THBS1 expression was positively correlated with scleral ECM remodeling. Von Willebrand factor (VWF), a glycoprotein that functions to bridge platelets with an exposed collagen surface, is associated with the severity of organ fibrosis [55]. These 13 core genes are the potential key genes that may be involved in scleral ECM remodeling.

The HIF-1 signaling pathway, one of the enriched KEGG pathways, has been shown to promote scleral myofibroblast transdifferentiation by regulating the actin cytoskeleton pathway, as well as ECM remodeling via the ECM receptor interaction pathway [35]. HIF-1α was shown to enhance VEGF-A expression and promote fibrinogenesis via the HIF-1α-VEGF pathway in bronchiolitis obliterans [56]. The TGFB pathway is acts as a primary signaling pathway in fibrogenesis by modulating the fibroblast phenotype and function, inducing myofibroblast transdifferentiation and α-SMA expression, and promoting matrix accumulation [57]. TGFB-signaling and the abundances of TGFB1, TGFB2 and TGFB-activating protein were found to be elevated in the sclera of glaucomatous eyes versus the control sclera [41]. Proteins in the FOXO family are growth factors and stress-regulated transcription factors that are involved in cellular differentiation, apoptosis, and cell proliferation. FOXO proteins can interact with TGFB-activated proteins to prevent fibrosis through β-catenin/FOXO1 signaling [58]. The PI3K-Akt signaling pathway is an important regulatory pathway that is involved in the regulation of cell proliferation, migration, differentiation and angiogenesis [59]. The PI3K-Akt signaling pathway also is involved in the pathological processes of fibrosis by regulating fibroblast migration and differentiation to myofibroblasts [60]. Inhibition of the PI3K/AKT signaling pathway was shown to prevent scarring of the filtering bleb of glaucoma filtration surgery by inhibiting human conjunctival fibroblast migration, proliferation and ECM synthesis [61]. These signaling pathways may play essential roles in the scleral stiffening associated with glaucoma.

Potential drugs identified by the drug-gene interaction search were classified as mainly TGFB inhibitors, VEGFA inhibitors, IGF inhibitors, fibrinolytic agents, antineoplastic agents, or immunomodulating agents. The TGFB inhibitors were mainly of hyaluronidase, lerdelimumab and fresolimumab. Hyaluronidases are enzymes that regulate the remodeling of ECM. Hyaluronidases have been shown to inhibit the growth of pulmonary fibrosis and decrease TGFB production and collagen deposition in mice [62]. Lerdelimumab is a monoclonal immunoglobulin antibody that specifically and potently neutralizes human TGFB2. Lerdelimumab was found to reduce subconjunctival fibrosis by inhibiting TGFB2-induced Tenon's fibroblast migration and proliferation in in vivo animal experiments [63]. Previous phase I and phase II clinical studies demonstrated that lerdelimumab reduced subconjunctival fibrosis in patients with primary glaucoma who had undergone trabeculectomy [64]. Fresolimumab is a monoclonal antibody of TGFB that reduced myofibroblast infiltration and inhibited TGFB-regulated gene expression in systemic sclerosis [65].

More than a quarter of identified drugs target VEGFA, including ranibizumab, bevacizumab, aflibercept, carvedilol, dalteparin sodium, phenytoin and vandetanib. Ranibizumab, a monoclonal antibody fragment against VEGF-A, inhibits vascular permeability and has antiproliferative and antimetabolic effects on various cell lines. Several studies have indicated that ranibizumab may prevent scarring after glaucoma filtering surgery through the VEGF pathway [66]. Bevacizumab is an IgG1 humanized monoclonal antibody that has been used to negate the effect of VEGF-A. Bevacizumab is approved by the US Food and Drug Administration. In clinical ophthalmology, bevacizumab has been used widely in the management of ophthalmic diseases, including choroidal neovascularization, diabetic macular edema and macular edema [67]. Aflibercept is a human fusion protein of the IgG Fc region and VEGF-receptor VEGF-A that also has been used widely in the management of ophthalmic diseases [68]. Carvedilol, is a nonselective-blocker that also has α1-adrenergic blocking, antioxidant and antiproliferative effects. Carvedilol was shown to attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway in human umbilical vascular endothelial cells [69]. Dalteparin sodium is a low molecular weight heparin that is used widely in the treatment of thromboembolisms. In rat, dalteparin sodium minimized hepatic fibrogenesis caused by chronic carbon tetrachloride treatment [70]. Vandetanib is an oral receptor tyrosine kinase inhibitor that potently inhibits VEGF receptor (VEGFR) tyrosine kinase activity. Vandetanib inhibits not only growth factor-induced phosphorylation of VEGFR and epidermal growth factor receptor (EGFR), but also mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) [71]. In mice, vandetanib reduced the degree of fibrosis on cutaneous wound healing [72].

Dusigitumab is a human antibody of IGF1 and IGF2. An in vivo experiment demonstrated that dusigitumab inhibited tumor growth of mouse embryonic fibroblast [73]. Sucralfate is a complex salt of sucrose sulfate and aluminum hydroxide that induces significant increases in the expression of EGF and TGFA in gastric mucosal cells [74]. Ocriplasmin, a recombinant protein with intrinsic action on collagen and fibronectin, is an effective nonsurgical treatment for vitreomacular traction. In rat, the intravitreal administration of microplasmin degraded fibronectin in the vitreoretinal interface and outer retina [75]. Urokinase, also known as urokinase-type plasminogen activator (uPA), is a strong plasminogen activator that is involved in cell migration, wound healing and tissue remodeling. The action of uPA on podocytes was found to be associated with the decreased prevalence of tubulointerstitial fibrosis [76]. Hydrochlorothiazide is a thiazide diuretic that is used in the treatment of hypertension and edema. In rat, hydrochlorothiazide was shown to reduce ischemic heart failure-induced fibrosis remodeling by inhibiting the angiotensin II signaling pathway [77]. Tretinoin, a retinoid metabolite of naturally occurring vitamin A, stimulated the formation of new collagen, stimulated fibroblasts, prevented collagen loss, and inhibited the induction of metalloproteinases [78]. Camptothecin is a DNA topoisomerase I inhibitor that blocks DNA synthesis and down-regulates THBS1 expression in human thyroid carcinoma FTC-133 cells through the JNK/ATF-2 pathway [79]. These drugs may have possible uses in the prevention of the scleral ECM remodeling in glaucoma. Further research is needed to confirm their possible new function.

Scleral ECM remodeling also is a key factor in the pathogenesis of myopia. In myopic human eyes, the sclera was found to be thinner, and the scleral ECM was decreased, compared with those in healthy eyes [80]. The thinner sclera and the associated decrease in the synthesis of collagen, proteoglycan, and other scleral matrix components also have been observed in animal models of myopia [81-83]. During myopia development, scleral ECM remodeling resulted in thinning of the sclera and reduced scleral resistance to IOP-related expansion which eventually contributed to excessive elongation of the ocular globe [84, 85]. Scleral stiffening has been proposed as a therapy for myopia, and the 26 drugs identified in this study may also be potential therapeutic agents for the treatment of myopia.

In conclusion, we identified 13 hub genes, VEGFA, TGFB1, TGFB2, TGFB3, IGF2, IGF1, EGF, FN1, KNG1, TIMP1, SERPINE1, THBS1 and VWF, that may be involved in the scleral ECM remodeling associated with glaucoma. These genes were enriched in the HIF-1 signaling pathway, FOXO signaling pathway, PI3K-Akt signaling pathway and TGFB signaling pathway. We also identified 26 potential drugs that may be help to guide future glaucoma therapies. The absence of experimental validation is a limitation of this study, and further experimental studies are required to verify the results.

Supplementary Material


Supplementary tables.


We thank Dr. Bin Zhao (Official Wechat Account: SCIPhD) of Sheng Xin Zhu Shou. We thank Margaret Biswas, PhD, from Liwen Bianji, Edanz Editing China (, for editing the English text of a draft of this manuscript.

Funding Support

This study was supported by Natural Science Foundation of Shanghai (18ZR1406000), National Science Foundation China (81790641).

Authors' Contributions

D.H., J.H.J and S.H.Q. conceived the study. D.H. and J.H.J collected the data. Z.L. and C.Z. performed the statistical analysis. D.H., J.H.J and Nived Moonasar wrote the paper. All authors read and approved the final manuscript.

Availability of data and materials

The authors declare that the data supporting the findings of this study are available within the article.

Competing Interests

The authors have declared that no competing interest exists.


1. Sun X, Dai Y, Chen Y. et al. Primary angle closure glaucoma: What we know and what we don't know. Prog Retin Eye Res. 2017;57:26-45

2. Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081-90

3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7

4. Leske MC, Heijl A, Hussein M. et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56

5. Drance SM. Some factors in the production of low tension glaucoma. Br J Ophthalmol. 1972;56:229-42

6. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy?. Surv Ophthalmol. 2007;52(Suppl 2):S162-73

7. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014;311:1901-11

8. Hernandez MR. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res. 2000;19:297-321

9. Hiraoka M, Inoue K, Ninomiya T, Takada M. Ischaemia in the Zinn-Haller circle and glaucomatous optic neuropathy in macaque monkeys. Br J Ophthalmol. 2012;96:597-603

10. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99:635-49

11. Nguyen C, Midgett D, Kimball EC. et al. Measuring Deformation in the Mouse Optic Nerve Head and Peripapillary Sclera. Invest Ophthalmol Vis Sci. 2017;58:721-33

12. Ebneter A, Wagels B, Zinkernagel MS. Non-invasive biometric assessment of ocular rigidity in glaucoma patients and controls. Eye (Lond). 2009;23:606-11

13. Coudrillier B, Tian J, Alexander S. et al. Biomechanics of the human posterior sclera: age- and glaucoma-related changes measured using inflation testing. Invest Ophthalmol Vis Sci. 2012;53:1714-28

14. Oglesby EN, Tezel G, Cone-Kimball E. et al. Scleral fibroblast response to experimental glaucoma in mice. Mol Vis. 2016;22:82-99

15. Cone-Kimball E, Nguyen C, Oglesby EN. et al. Scleral structural alterations associated with chronic experimental intraocular pressure elevation in mice. Mol Vis. 2013;19:2023-39

16. Sigal IA, Flanagan JG, Tertinegg I, Ethier CR. Finite element modeling of optic nerve head biomechanics. Invest Ophthalmol Vis Sci. 2004;45:4378-87

17. Coudrillier B, Campbell IC, Read AT. et al. Effects of Peripapillary Scleral Stiffening on the Deformation of the Lamina Cribrosa. Invest Ophthalmol Vis Sci. 2016;57:2666-77

18. Wu HJ, Kuchtey J, Kuchtey RW. Increased Susceptibility to Glaucomatous Damage in Microfibril Deficient Mice. Invest Ophthalmol Vis Sci. 2020;61:28

19. Kimball EC, Nguyen C, Steinhart MR. et al. Experimental scleral cross-linking increases glaucoma damage in a mouse model. Exp Eye Res. 2014;128:129-40

20. Moosavinasab S, Patterson J, Strouse R. et al. 'RE:fine drugs': an interactive dashboard to access drug repurposing opportunities. Database (Oxford). 2016. 2016

21. Mosca E, Bertoli G, Piscitelli E. et al. Identification of functionally related genes using data mining and data integration: a breast cancer case study. BMC Bioinformatics. 2009;10(Suppl 12):S8

22. Berg EL. Systems biology in drug discovery and development. Drug Discov Today. 2014;19:113-25

23. Yu S, Tranchevent LC, De Moor B, Moreau Y. Gene prioritization and clustering by multi-view text mining. BMC Bioinformatics. 2010;11:28

24. Nogales-Cadenas R, Carmona-Saez P, Vazquez M. et al. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 2009;37:W317-22

25. von Mering C, Huynen M, Jaeggi D. et al. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31:258-61

26. Smoot ME, Ono K, Ruscheinski J. et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;27:431-2

27. Bandettini WP, Kellman P, Mancini C. et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83

28. Huang DW, Sherman BT, Tan Q. et al. The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 2007;8(9):R183

29. Dennis G Jr, Sherman BT, Hosack DA. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3

30. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30

31. Bindea G, Mlecnik B, Hackl H. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091-3

32. Cotto KC, Wagner AH, Feng YY. et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46:D1068-d73

33. Chauhan BC, Drance SM. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1992;230:521-6

34. Christian PG, Harkin DG, Schmid KL. GABAergic agents modify the response of chick scleral fibroblasts to myopic and hyperopic eye cup tissues. Curr Eye Res. 2014;39:172-87

35. Wu H, Chen W, Zhao F. et al. Scleral hypoxia is a target for myopia control. Proc Natl Acad Sci U S A. 2018;115:E7091-e100

36. Girard MJ, Suh JK, Bottlang M. et al. Scleral biomechanics in the aging monkey eye. Invest Ophthalmol Vis Sci. 2009;50:5226-37

37. Grytz R, Yang H, Hua Y. et al. Connective Tissue Remodeling in Myopia and its Potential Role in Increasing Risk of Glaucoma. Curr Opin Biomed Eng. 2020;15:40-50

38. Cui W, Bryant MR, Sweet PM, McDonnell PJ. Changes in gene expression in response to mechanical strain in human scleral fibroblasts. Exp Eye Res. 2004;78:275-84

39. Huo L, Cui D, Yang X. et al. All-trans retinoic acid modulates mitogen-activated protein kinase pathway activation in human scleral fibroblasts through retinoic acid receptor beta. Mol Vis. 2013;19:1795-803

40. Yang J, Zhang Y, Xu X. et al. Transforming growth factor-β is involved in maintaining oocyte meiotic arrest by promoting natriuretic peptide type C expression in mouse granulosa cells. Cell Death Dis. 2019;10:558

41. Pitha I, Oglesby E, Chow A. et al. Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma. Transl Vis Sci Technol. 2018;7:6

42. Krenn K, Klepetko W, Taghavi S. et al. Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation. Eur J Cardiothorac Surg. 2007;32:35-41

43. Kariya T, Nishimura H, Mizuno M. et al. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis. Am J Physiol Renal Physiol. 2018;314:F167-f80

44. Van Bergen T, Vandewalle E, Van de Veire S. et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93:689-99

45. Uh ST, Inoue Y, King TE Jr. et al. Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1626-35

46. Giraudi PJ, Gambaro SE, Ornelas Arroyo S. et al. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. Liver Int. 2018;38:155-63

47. Xu H, Liu L, Cong M. et al. EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. Histochemistry and cell biology. 2020;154:107-16

48. Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol. 2008;20:495-501

49. Tomasek JJ, Gabbiani G, Hinz B. et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349-63

50. Tuan TL, Hwu P, Ho W. et al. Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts. Am J Pathol. 2008;173:1311-25

51. Colman RW. Biologic activities of the contact factors in vivo-potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost. 1999;82:1568-77

52. Dong J, Ma Q. TIMP1 promotes multi-walled carbon nanotube-induced lung fibrosis by stimulating fibroblast activation and proliferation. Nanotoxicology. 2017;11:41-51

53. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36:961-8

54. Gao H, Frost MR, Siegwart JT Jr, Norton TT. Patterns of mRNA and protein expression during minus-lens compensation and recovery in tree shrew sclera. Mol Vis. 2011;17:903-19

55. Plompen EP, Darwish Murad S, Hansen BE. et al. Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study. J Hepatol. 2015;63:1459-65

56. Xu H, Abuduwufuer A, Lv W. et al. The role of HIF-1α-VEGF pathway in bronchiolitis obliterans after lung transplantation. J of Cardiothoracic Surgery. 2019;14:27

57. Duncan MR, Frazier KS, Abramson S. et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. Faseb j. 1999;13:1774-86

58. Rao P, Pang M, Qiao X. et al. Promotion of β-catenin/Foxo1 signaling ameliorates renal interstitial fibrosis. Lab Invest. 2019;99:1689-701

59. Zhang H, Bajraszewski N, Wu E. et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007;117:730-8

60. Li G, Li YY, Sun JE. et al. ILK-PI3K/AKT pathway participates in cutaneous wound contraction by regulating fibroblast migration and differentiation to myofibroblast. Lab Invest. 2016;96:741-51

61. Liang L, Wang X, Zheng Y, Liu Y. All-trans-retinoic acid modulates TGF-β-induced apoptosis, proliferation, migration and extracellular matrix synthesis of conjunctival fibroblasts by inhibiting PI3K/AKT signaling. Mol Med Rep. 2019;20:2929-35

62. Bitencourt CS, Pereira PA, Ramos SG. et al. Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis. Fibrogenesis Tissue Repair. 2011;4:3

63. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-34

64. Siriwardena D, Khaw PT, King AJ. et al. Human antitransforming growth factor beta(2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology. 2002;109:427-31

65. Rice LM, Padilla CM, McLaughlin SR. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125:2795-807

66. Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol. 2010;150:399-403.e1

67. Chakravarthy U, Harding SP, Rogers CA. et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258-67

68. Sangroongruangsri S, Ratanapakorn T, Wu O. et al. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol. 2018;11:903-16

69. Ding Q, Tian XG, Li Y. et al. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol. 2015;21:9566-76

70. Abe W, Ikejima K, Lang T. et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46:286-94

71. Sarkar S, Mazumdar A, Dash R. et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther. 2010;9:592-603

72. Ko J, Ross J, Awad H. et al. The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res. 2005;129:251-9

73. Gao J, Chesebrough JW, Cartlidge SA. et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 2011;71:1029-40

74. Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment?. Scand J Gastroenterol Suppl. 1995;210:9-14

75. Chen W, Mo W, Sun K. et al. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res. 2009;34:1057-64

76. Lee JH, Oh MH, Park JS. et al. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis. Korean J Intern Med. 2014;29:176-82

77. Luo J, Chen X, Luo C. et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 35

78. Baldwin HE, Nighland M, Kendall C. et al. 40 years of topical tretinoin use in review. J Drugs Dermatol. 2013;12:638-42

79. El Btaouri H, Morjani H, Greffe Y. et al. Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells. Biochim Biophys Acta. 2011;1813:695-703

80. Avetisov ES, Savitskaya NF, Vinetskaya MI, Iomdina EN. A study of biochemical and biomechanical qualities of normal and myopic eye sclera in humans of different age groups. Metab Pediatr Syst Ophthalmol. 1983;7:183-8

81. McBrien NA, Gentle A. Role of the sclera in the development and pathological complications of myopia. Prog Retin Eye Res. 2003;22:307-38

82. Rada JA, Nickla DL, Troilo D. Decreased proteoglycan synthesis associated with form deprivation myopia in mature primate eyes. Invest Ophthalmol Vis Sci. 2000;41:2050-8

83. McBrien NA, Cornell LM, Gentle A. Structural and ultrastructural changes to the sclera in a mammalian model of high myopia. Invest Ophthalmol Vis Sci. 2001;42:2179-87

84. Grytz R, Siegwart JT Jr. Changing material properties of the tree shrew sclera during minus lens compensation and recovery. Invest Ophthalmol Vis Sci. 2015;56:2065-78

85. Sergienko NM, Shargorogska I. The scleral rigidity of eyes with different refractions. Graefes Arch Clin Exp Ophthalmol. 2012;250:1009-12

Author contact

Corresponding address Corresponding author: Shaohong Qian, Prof, MD. Department of Ophthalmology, Eye and Ear, Nose, Throat Hospital, Shanghai Medical College, Fudan University, Shanghai, China. No.83 Fenyang Road, Shanghai, 200031, China. E-mail: qsh2304com.

Received 2020-9-4
Accepted 2021-1-5
Published 2021-2-4